The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study
BackgroundImmune checkpoint inhibitors (ICIs) combined with chemotherapy have become a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the optimal sequence of administrating the two treatments remains controversial.MethodsThis study included advanced NSCLC pat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579420/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849310609742495744 |
|---|---|
| author | Bicheng Zhang Yuxiao Song Qian Min Weiting Cheng Jun Wang Yang Fu Jiaxin Yin |
| author_facet | Bicheng Zhang Yuxiao Song Qian Min Weiting Cheng Jun Wang Yang Fu Jiaxin Yin |
| author_sort | Bicheng Zhang |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) combined with chemotherapy have become a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the optimal sequence of administrating the two treatments remains controversial.MethodsThis study included advanced NSCLC patients who received ICIs combined with chemotherapy at Renmin Hospital of Wuhan University and Xiangyang Hospital, Hubei University of Chinese Medicine between 1st September 2020 and 30th September 2024. Patients were categorized into the concurrent, immune-chemo, and chemo-immune groups based on different sequences of treatment administration. The primary endpoints evaluated were survival and treatment efficacy. The secondary endpoint assessed was treatment-related adverse events (TRAEs).ResultsThis two-center, retrospective study included 270 NSCLC patients who received ICIs plus chemotherapy. Survival analysis revealed statistically significant differences across treatment groups. The median overall survival (mOS) durations were 636 days (concurrent group), 615 days (immune-chemo group), and 749 days (chemo-immune group), with a log-rank test demonstrating significant intergroup differences (P = 0.0017). Similarly, median progression-free survival (mPFS) showed distinct patterns at 178 days, 180 days, and 216 days for the respective groups (log-rank P = 0.0134). Additionally, the objective response rates (ORRs) for the three groups were 55.82% (72/129), 58.21% (39/67), and 68.92% (51/74), respectively. The incidence of TRAEs of any grade in the concurrent, the immune-chemo, and the chemo-immune groups was 77.52% (100/129), 65.67% (44/67), and 59.46% (44/74) rates, respectively, which was a significant difference (χ²=7.91, P=0.019). Despite patients experiencing Grade 3 or higher TRAEs had extremely poor prognoses, overall, patients who developed any grade of TRAEs had better survival outcomes, particularly those with skin or endocrine toxicity.ConclusionsThese findings suggest that the administration sequence of chemotherapy followed by ICIs may yield the greatest clinical benefit, providing a basis for clinical decision-making. |
| format | Article |
| id | doaj-art-d176175172f442c080634baaad4efa14 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d176175172f442c080634baaad4efa142025-08-20T03:53:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15794201579420The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective studyBicheng Zhang0Yuxiao Song1Qian Min2Weiting Cheng3Jun Wang4Yang Fu5Jiaxin Yin6Cancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, ChinaDepartment of Oncology and Hematology, Xiangyang Hospital, Hubei University of Chinese Medicine, Xiangyang, ChinaCancer Center, Renmin Hospital of Wuhan University, Wuhan, ChinaBackgroundImmune checkpoint inhibitors (ICIs) combined with chemotherapy have become a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). However, the optimal sequence of administrating the two treatments remains controversial.MethodsThis study included advanced NSCLC patients who received ICIs combined with chemotherapy at Renmin Hospital of Wuhan University and Xiangyang Hospital, Hubei University of Chinese Medicine between 1st September 2020 and 30th September 2024. Patients were categorized into the concurrent, immune-chemo, and chemo-immune groups based on different sequences of treatment administration. The primary endpoints evaluated were survival and treatment efficacy. The secondary endpoint assessed was treatment-related adverse events (TRAEs).ResultsThis two-center, retrospective study included 270 NSCLC patients who received ICIs plus chemotherapy. Survival analysis revealed statistically significant differences across treatment groups. The median overall survival (mOS) durations were 636 days (concurrent group), 615 days (immune-chemo group), and 749 days (chemo-immune group), with a log-rank test demonstrating significant intergroup differences (P = 0.0017). Similarly, median progression-free survival (mPFS) showed distinct patterns at 178 days, 180 days, and 216 days for the respective groups (log-rank P = 0.0134). Additionally, the objective response rates (ORRs) for the three groups were 55.82% (72/129), 58.21% (39/67), and 68.92% (51/74), respectively. The incidence of TRAEs of any grade in the concurrent, the immune-chemo, and the chemo-immune groups was 77.52% (100/129), 65.67% (44/67), and 59.46% (44/74) rates, respectively, which was a significant difference (χ²=7.91, P=0.019). Despite patients experiencing Grade 3 or higher TRAEs had extremely poor prognoses, overall, patients who developed any grade of TRAEs had better survival outcomes, particularly those with skin or endocrine toxicity.ConclusionsThese findings suggest that the administration sequence of chemotherapy followed by ICIs may yield the greatest clinical benefit, providing a basis for clinical decision-making.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579420/fullimmune checkpoint inhibitorschemotherapyadministration sequenceefficacynon-small cell lung cancer |
| spellingShingle | Bicheng Zhang Yuxiao Song Qian Min Weiting Cheng Jun Wang Yang Fu Jiaxin Yin The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study Frontiers in Immunology immune checkpoint inhibitors chemotherapy administration sequence efficacy non-small cell lung cancer |
| title | The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study |
| title_full | The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study |
| title_fullStr | The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study |
| title_full_unstemmed | The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study |
| title_short | The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study |
| title_sort | administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non small cell lung cancer a retrospective study |
| topic | immune checkpoint inhibitors chemotherapy administration sequence efficacy non-small cell lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579420/full |
| work_keys_str_mv | AT bichengzhang theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT yuxiaosong theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT qianmin theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT weitingcheng theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT junwang theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT yangfu theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT jiaxinyin theadministrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT bichengzhang administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT yuxiaosong administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT qianmin administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT weitingcheng administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT junwang administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT yangfu administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy AT jiaxinyin administrationsequencesofimmunecheckpointinhibitorsandchemotherapycausediscreteefficacywhentreatingnonsmallcelllungcanceraretrospectivestudy |